Exsurco Medical

Executive Summary

Exsurco Medical is a privately held medical device company headquartered in Salt Lake City, Utah, dedicated to advancing dermatome technology for skin graft harvesting and wound debridement. Founded in 2016, the company serves two distinct markets: tissue banks, where its devices enable efficient recovery of cadaveric allografts, and hospitals/surgical centers, where its products facilitate live patient autografting and debridement. Exsurco's core mission is to improve recovery times and tissue yields for burn and wound care patients, addressing critical needs in a market characterized by aging legacy devices and increasing demand for skin grafts. Despite being in a niche segment, the company is well-positioned to capitalize on the growing prevalence of chronic wounds and burn injuries, supported by an experienced management team and a focus on innovation. Exsurco's devices are designed to enhance precision, reduce waste, and optimize graft quality, which can lead to better patient outcomes and lower healthcare costs. With no disclosed funding or revenue, the company operates in a capital-intensive industry; however, its differentiated technology and targeted market approach suggest significant potential for growth and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for next-generation dermatome70% success
• Q2 2026Strategic partnership with a major burn center or tissue bank50% success
• H1 2027Expansion into European or Asian markets via distribution agreement40% success